Association of increased survival in glioblastoma patients treated with dendritic cell vaccinations and temozolomide with increased activity of NK cells and ABCC3 expression.
/in Dendritic Cells, Glioblastoma, International PublicationsEmerging immunotherapies for glioblastoma
/in Checkpoint-Inhibitors, Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease VirusDendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma
/in Dendritic Cells, Glioblastoma, Immunogenic Cell Death, International Publications, Prostate CancerElectro-hyperthermia inhibits glioma tumorigenicity through the induction of E2F1-mediated apoptosis
/in Glioblastoma, Hyperthermia, International PublicationsIrradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma
/in Dendritic Cells, Glioblastoma, International Publications, IOZK VeröffentlichungenTumour Relapse Prediction Using Multiparametric MR Data Recorded during Follow-Up of GBM Patients
/in Glioblastoma, International Publications, IOZK VeröffentlichungenEx vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma
/in Dendritic Cells, Glioblastoma, International PublicationsDendritic cell-based immunotherapy targeting Wilms‘ tumor 1 in patients with recurrent malignant glioma
/in Dendritic Cells, Glioblastoma, International PublicationsPhase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).
/in Dendritic Cells, Glioblastoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer